Teligent Comprehensive Income 2010-2021 | TLGT

Teligent comprehensive income from 2010 to 2021. Comprehensive income can be defined as the change in net assets of a business enterprise during a period from transactions and other events and circumstances from nonowner sources. It includes all changes in equity during a period except those resulting from investments by owners and distributions to owners.
Teligent Annual Comprehensive Income
(Millions of US $)
2020 $-2
2019 $-2
2018 $-3
2017 $-2
2016 $-2
2015 $0
2014 $0
2013 $0
2012 $0
2011 $0
2010 $0
2009 $0
Teligent Quarterly Comprehensive Income
(Millions of US $)
2021-06-30 $-3
2021-03-31 $-3
2020-12-31 $-2
2020-09-30 $-3
2020-06-30 $-3
2020-03-31 $-3
2019-12-31 $-2
2019-09-30 $-2
2019-06-30 $-2
2019-03-31 $-3
2018-12-31 $-3
2018-09-30 $-2
2018-06-30 $-2
2018-03-31 $-2
2017-12-31 $-2
2017-09-30 $-1
2017-06-30 $-2
2017-03-31 $-2
2016-12-31 $-2
2016-09-30 $-1
2016-06-30 $-1
2016-03-31 $0
2015-12-31 $0
2015-09-30
2015-06-30
2015-03-31
2014-12-31
2014-09-30
2014-06-30
2014-03-31
2013-12-31
2013-09-30
2013-06-30
2013-03-31
2012-12-31
2012-09-30
2012-06-30
2012-03-31
2011-12-31
2011-09-30
2011-06-30
2011-03-31
2010-12-31
2010-09-30
2010-06-30
2010-03-31
2009-12-31
2009-09-30
2009-06-30
2009-03-31
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $0.000B $0.000B
Teligent, Inc. is a specialty generic pharmaceutical company, develops, manufactures and markets topical formulations primarily in the United States. It sells generic pharmaceutical products in topical, injectable, complex and ophthalmic dosage forms. Teligent Inc., formerly known as IGI Laboratories, Inc., is based in Buena, New Jersey.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $18.277B 6.69
Dr Reddy's Laboratories (RDY) India $11.278B 21.51
BridgeBio Pharma (BBIO) United States $7.014B 0.00
Supernus Pharmaceuticals (SUPN) United States $1.816B 14.74
Bausch Health Cos (BHC) Canada $1.716B 1.26
Amphastar Pharmaceuticals (AMPH) United States $1.134B 6.86
Taysha Gene Therapies (TSHA) United States $0.410B 0.00
Personalis (PSNL) United States $0.353B 0.00
Assembly Biosciences (ASMB) United States $0.097B 0.00
Sol-Gel Technologies (SLGL) Israel $0.021B 0.00
Evoke Pharma (EVOK) United States $0.005B 0.00